JP6588893B2 - 卵巣がんの自己抗体バイオマーカー - Google Patents

卵巣がんの自己抗体バイオマーカー Download PDF

Info

Publication number
JP6588893B2
JP6588893B2 JP2016515521A JP2016515521A JP6588893B2 JP 6588893 B2 JP6588893 B2 JP 6588893B2 JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016515521 A JP2016515521 A JP 2016515521A JP 6588893 B2 JP6588893 B2 JP 6588893B2
Authority
JP
Japan
Prior art keywords
ovarian cancer
autoantibodies
autoantibody
subject
anxa1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016515521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536568A (ja
JP2016536568A5 (https=
Inventor
ホフマン ピーター
ホフマン ピーター
オーラー マーティン
オーラー マーティン
マーティン カリーナ
マーティン カリーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation and Commercial Partners Pty Ltd
Original Assignee
Adelaide Research and Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903595A external-priority patent/AU2013903595A0/en
Application filed by Adelaide Research and Innovation Pty Ltd filed Critical Adelaide Research and Innovation Pty Ltd
Publication of JP2016536568A publication Critical patent/JP2016536568A/ja
Publication of JP2016536568A5 publication Critical patent/JP2016536568A5/ja
Application granted granted Critical
Publication of JP6588893B2 publication Critical patent/JP6588893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016515521A 2013-09-18 2014-09-18 卵巣がんの自己抗体バイオマーカー Active JP6588893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903595A AU2013903595A0 (en) 2013-09-18 Autoantibody biomarkers of ovarian cancer
AU2013903595 2013-09-18
PCT/AU2014/000925 WO2015039175A1 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Publications (3)

Publication Number Publication Date
JP2016536568A JP2016536568A (ja) 2016-11-24
JP2016536568A5 JP2016536568A5 (https=) 2017-10-26
JP6588893B2 true JP6588893B2 (ja) 2019-10-09

Family

ID=52687999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515521A Active JP6588893B2 (ja) 2013-09-18 2014-09-18 卵巣がんの自己抗体バイオマーカー

Country Status (7)

Country Link
US (3) US20160291025A1 (https=)
EP (1) EP3047277B1 (https=)
JP (1) JP6588893B2 (https=)
CN (1) CN105745543B (https=)
AU (1) AU2014324080B2 (https=)
CA (1) CA2924600A1 (https=)
WO (1) WO2015039175A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056888A (zh) * 2017-03-01 2017-08-18 中山大学肿瘤防治中心 Atp1a1靶向多肽及应用
CN109116024B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-actr3自身抗体及其应用
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
US20240186001A1 (en) * 2019-10-16 2024-06-06 Icahn School Of Medicine At Mount Sinai Systems and methods for detecting a disease condition
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054805A1 (en) * 1999-03-15 2000-09-21 University Of Maryland, Baltimore SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
AU2001253104A1 (en) * 2000-04-03 2001-10-15 Gesellschaft Fur Biotechnologische Forschung Gmbh Methods for altering t cell and macrophage activation
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
CN101268367A (zh) * 2005-06-24 2008-09-17 赛弗吉生物系统公司 卵巢癌的生物标记
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
JP5495159B2 (ja) * 2006-09-13 2014-05-21 オンクイミューン リミテッド 改善されたイムノアッセイ法
WO2008115710A2 (en) * 2007-03-07 2008-09-25 The Johns Hopkins University Biomarkers for cancer
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
US8664358B2 (en) * 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
CA2705272C (en) * 2007-11-13 2020-05-12 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
WO2010070043A1 (en) * 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers for the diagnosis of renal allograft and kidney status
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
CN101762699A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法
US20120277326A1 (en) 2009-11-20 2012-11-01 Taylor Douglas D Biomarkers of cancer
JP2011257147A (ja) * 2010-06-04 2011-12-22 Nitto Boseki Co Ltd データ収集方法、キット及び腫瘍マーカー
WO2013112801A1 (en) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
JP5574348B2 (ja) * 2012-05-31 2014-08-20 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
US20140179808A1 (en) * 2012-10-23 2014-06-26 Bio-Rad Laboratories, Inc. Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens
JP2016507748A (ja) 2013-01-31 2016-03-10 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 卵巣癌の早期発見のための自己抗体サイン

Also Published As

Publication number Publication date
US20220365088A1 (en) 2022-11-17
JP2016536568A (ja) 2016-11-24
AU2014324080B2 (en) 2020-07-23
US12287337B2 (en) 2025-04-29
CA2924600A1 (en) 2015-03-26
US20160291025A1 (en) 2016-10-06
CN105745543A (zh) 2016-07-06
EP3047277A1 (en) 2016-07-27
WO2015039175A1 (en) 2015-03-26
EP3047277A4 (en) 2017-05-10
US20190219584A1 (en) 2019-07-18
CN105745543B (zh) 2018-02-02
US11371993B2 (en) 2022-06-28
AU2014324080A1 (en) 2016-04-14
EP3047277B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
JP6588893B2 (ja) 卵巣がんの自己抗体バイオマーカー
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
JP2010518847A (ja) タンパク質
CN104755496A (zh) 作为癌症治疗和诊断靶标的ly75
EP2239576A1 (en) Composition and method for diagnosis or detection of gastric cancer
JP2011509079A (ja) エフリンａ型受容体１０タンパク質
KR20170137848A (ko) 폐암을 치료하는 방법
AU2008284271B2 (en) Matriptase protein and uses thereof
TWI667479B (zh) 乳癌生物標記
JP6523968B2 (ja) 治療的及び診断的標的としての不活性Ｎ−アセチル化−α−結合型酸性ジペプチダーゼ−様タンパク質２（ＮＡＡＬＡＤＬ２）
CA3106191A1 (en) Methods for differentiating benign prostatic hyperplasia from prostate cancer
JP2012511894A (ja) Ｐｔａ０７２タンパク質
JP7384365B2 (ja) 口腔乾燥症を診断するための唾液バイオマーカー及びその用途
US20130323253A1 (en) Xyxin fragment biomarker for diagnosis of colon cancer
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
US20120058131A1 (en) Pta089 protein
WO2022091793A1 (ja) 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発
WO2024172145A1 (ja) 腎細胞癌検出用バイオマーカー
US20090214540A1 (en) Protein involved in cancer
WO2020162441A1 (ja) 肉芽腫性疾患バイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190913

R150 Certificate of patent or registration of utility model

Ref document number: 6588893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250